Aleksandra Pesic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aleksandra Pesic has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Bradly G. Wouters
Princess Margaret Cancer Center, University Health Network
41 shared publications - Anthony Michael Joshua
Kinghorn Cancer Centre, St Vincent's Hospital Sydney Australia
40 shared publications Zvi Shalev
40 shared publicationsAdam Sharp
25 shared publications- Amanda Mawson
Pancreatic Cancer Translational Research Group, School of Biomedical Sciences, Lowy Cancer Research Centre, UNSW Sydney; NSW 2052, Australia; Garvan Institute of Medical Research; NSW 2010, Australia
25 shared publications Amina Zoubeidi
25 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Clinical Trial Protocol from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Detailed protocol of the HYDRA-1 (NCT03081702) Trial. TITLE: A phase I/II trial investigating the tolerability, toxicity and efficacy of hydroxychloroquine and itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-1 study).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessClinical Trial Protocol from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Detailed protocol of the HYDRA-1 (NCT03081702) Trial. TITLE: A phase I/II trial investigating the tolerability, toxicity and efficacy of hydroxychloroquine and itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-1 study).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary File 2 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
CRISPR screen TOV1946. Results of the Itra sensitizing CRISPR screen on the TOV1946 cell line using drugZ algorithm.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 2 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
CRISPR screen TOV1946. Results of the Itra sensitizing CRISPR screen on the TOV1946 cell line using drugZ algorithm.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
CRISPR screen OVCAR5. Results of the Itra sensitizing CRISPR screen on the OVCAR5 cell line using drugZ algorithm.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
CRISPR screen OVCAR5. Results of the Itra sensitizing CRISPR screen on the OVCAR5 cell line using drugZ algorithm.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
CRISPR screen OVCAR5. Results of the Itra sensitizing CRISPR screen on the OVCAR5 cell line using drugZ algorithm.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
CRISPR screen OVCAR5. Results of the Itra sensitizing CRISPR screen on the OVCAR5 cell line using drugZ algorithm.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
- List of cell lines- Lentiviral constructs, lentivirus generation and infection- Apoptosis Assay- FILIPIN staining- Lysosomal assay and immunofluorescence
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
- List of cell lines- Lentiviral constructs, lentivirus generation and infection- Apoptosis Assay- FILIPIN staining- Lysosomal assay and immunofluorescence
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-7 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Supplementary Figure 1: Itra dose response in ovarian cancer cell lines. - Supplementary Figure 2: Analysis on ovarian cancer cell lines used in the Itra-sensitizing CRISPR screen (OVCAR5 and TOV1946). - Supplementary Figure 3: c18orf8 and VPS54 Knockout effects on the TOV1946 cell line. - Supplementary Figure 4: Itra+CQ dose responses. - Supplementary Figure 5: 5/10 uM CQ response and apoptosis assay results. - Supplementary Figure 6: Itra+CQ dose response in c18orf8 and VPS54 knockout cells and calculation of synergy scores. - Supplementary Figure 7: Intratumoural Itra/CQ detection and Ki-67 analysis in patient samples.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-7 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Supplementary Figure 1: Itra dose response in ovarian cancer cell lines. - Supplementary Figure 2: Analysis on ovarian cancer cell lines used in the Itra-sensitizing CRISPR screen (OVCAR5 and TOV1946). - Supplementary Figure 3: c18orf8 and VPS54 Knockout effects on the TOV1946 cell line. - Supplementary Figure 4: Itra+CQ dose responses. - Supplementary Figure 5: 5/10 uM CQ response and apoptosis assay results. - Supplementary Figure 6: Itra+CQ dose response in c18orf8 and VPS54 knockout cells and calculation of synergy scores. - Supplementary Figure 7: Intratumoural Itra/CQ detection and Ki-67 analysis in patient samples.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-7 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Supplementary Figure 1: Itra dose response in ovarian cancer cell lines. - Supplementary Figure 2: Analysis on ovarian cancer cell lines used in the Itra-sensitizing CRISPR screen (OVCAR5 and TOV1946). - Supplementary Figure 3: c18orf8 and VPS54 Knockout effects on the TOV1946 cell line. - Supplementary Figure 4: Itra+CQ dose responses. - Supplementary Figure 5: 5/10 uM CQ response and apoptosis assay results. - Supplementary Figure 6: Itra+CQ dose response in c18orf8 and VPS54 knockout cells and calculation of synergy scores. - Supplementary Figure 7: Intratumoural Itra/CQ detection and Ki-67 analysis in patient samples.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-7 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Supplementary Figure 1: Itra dose response in ovarian cancer cell lines. - Supplementary Figure 2: Analysis on ovarian cancer cell lines used in the Itra-sensitizing CRISPR screen (OVCAR5 and TOV1946). - Supplementary Figure 3: c18orf8 and VPS54 Knockout effects on the TOV1946 cell line. - Supplementary Figure 4: Itra+CQ dose responses. - Supplementary Figure 5: 5/10 uM CQ response and apoptosis assay results. - Supplementary Figure 6: Itra+CQ dose response in c18orf8 and VPS54 knockout cells and calculation of synergy scores. - Supplementary Figure 7: Intratumoural Itra/CQ detection and Ki-67 analysis in patient samples.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary File 2 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
CRISPR screen TOV1946. Results of the Itra sensitizing CRISPR screen on the TOV1946 cell line using drugZ algorithm.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 2 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
CRISPR screen TOV1946. Results of the Itra sensitizing CRISPR screen on the TOV1946 cell line using drugZ algorithm.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-5 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Supplementary Tables 1 and 2 show respectively the fold change of lysosomal function and size in treated sensitive/resistant cells obtained by mixed effect modelling. Supplementary Table 3 shows patients enrolled per dose-level (DL) and dose limiting toxicities (DLTs). Supplementary Tables 4 and 5 show the summary of all and treatment related adverse effects.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-5 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Supplementary Tables 1 and 2 show respectively the fold change of lysosomal function and size in treated sensitive/resistant cells obtained by mixed effect modelling. Supplementary Table 3 shows patients enrolled per dose-level (DL) and dose limiting toxicities (DLTs). Supplementary Tables 4 and 5 show the summary of all and treatment related adverse effects.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
- List of cell lines- Lentiviral constructs, lentivirus generation and infection- Apoptosis Assay- FILIPIN staining- Lysosomal assay and immunofluorescence
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
- List of cell lines- Lentiviral constructs, lentivirus generation and infection- Apoptosis Assay- FILIPIN staining- Lysosomal assay and immunofluorescence